Page Title
Clinical Trial Finder
Anti-Inflammatory Closed to Enrollment
Study to evaluate CB-280 in adults with cystic fibrosis and chronic Pseudomonas aeruginosa (Calithera CX-280-202 )
This study will look at the safety and tolerability of CB-280, an oral drug taken twice a day intended to treat infections in the lung and reduce inflammation. Multiple doses of the drug will be tested in adults with cystic fibrosis and chronic Pseudomonas aeruginosa to find the best dose.
This is a placebo-controlled study, meaning that some participants will receive CB-280 and others will receive a placebo. Researchers will test the safety and tolerability of CB-280 by monitoring for adverse events. They will also assess how the body processes the drug by measuring how much of the drug stays in the body.This study is for adults with cystic fibrosis who have chronic Pseudomonas aeruginosa. This study may require blood draws, lung function tests, and/or other measures.
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
40 to 90%
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Participants must have a history of at least two positive sputum cultures for Pseudomonas aeruginosa in the past year.
Study Design
-
Study Type: ?more info
Interventional -
Randomized Study: ?more info
Yes -
Placebo Controlled: ?more info
Yes -
Length of Participation:
2 months -
Number of Study Visits:
6
Additional Information
-
Phase: ?more info
Phase One -
Study Sponsor: ?more info
Calithera Biosciences -
Study Drugs:
Study Sites
-
Closed to Enrollment
Arkansas
University of Arkansas for Medical Sciences, Little Rock, AR 72205
-
Closed to Enrollment
California
Long Beach Memorial Medical Center, Long Beach, CA 90806
-
Closed to Enrollment
Florida
University of Florida, Gainesville, FL 32610
-
Closed to Enrollment
Illinois
CF Center Chicago (Glenview, Il), Glenview, IL 60025
-
Closed to Enrollment
Indiana
Indiana University Medical Center, Indianapolis, IN 46202
-
Closed to Enrollment
Kansas
University of Kansas Medical Center, Kansas City, KS 66160
-
Closed to Enrollment
Maryland
Johns Hopkins University, Baltimore, MD 21205
-
Closed to Enrollment
Massachusetts
Boston Children's Hospital, Brigham & Women's Hospital, Boston, MA 02115
-
Closed to Enrollment
Montana
Billings Clinic, Billings, MT 59107
-
Closed to Enrollment
New York
New York Medical College at Westchester Medical Center, Valhalla, NY 10595
-
Closed to Enrollment
North Carolina
University of North Carolina at Chapel Hill, Chapel Hill, NC 27599
-
Closed to Enrollment
Ohio
Rainbow Babies and Children's Hospital/University Hospitals Cleveland Medical Center, Cleveland, OH 44106
-
Closed to Enrollment
Pennsylvania
Hershey Medical Center Pennsylvania State University, Hershey, PA 17033
-
Closed to Enrollment
South Carolina
Medical University of South Carolina, Charleston, SC 29425
-
Closed to Enrollment
Utah
Primary Children's Cystic Fibrosis Center, Salt Lake City, UT 84113
-
Closed to Enrollment
Vermont
University of Vermont Medical Center, Burlington, VT 05401
-
Closed to Enrollment
Virginia
Virginia Commonwealth University, Richmond, VA 23298
Eligibility
See other primary eligibility criteria for more information.
-
Age:
18 Years and Older -
Mutation(s):
No Mutation Requirement -
FEV1% Predicted:
40 to 90% -
Pseudomonas Status:
Positive Respiratory Cultures Required
For more information about the results of this study and where it was conducted, visit ClinicalTrials.gov.
Other Primary Eligibility Criteria
Participants must have a history of at least two positive sputum cultures for Pseudomonas aeruginosa in the past year.
Sign up for clinical trial alerts
Get email updates about clinical trials that matter to you.
Check the Drug Development Pipeline
We’re attacking CF from every angle. Learn about the status of CF drugs in development.
Learn More